Location: Chicago, United States
Date: May 31 to June 4
American Society of Clinical Oncology.
Will There Ever Be Progress for Leptomeningeal Carcinomatosis: An Update on the Multidisciplinary Management in the Setting of Immuno-Oncology and Precision Medicine
Highlights of prostate cancer research at ASCO2019
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.
To Infinity and Beyond: The Future of Immunotherapy in Gynecologic Malignancies
Hematologic Malignancies—Plasma Cell Dyscrasia
ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS)
Targeting Breast Cancer: Breaking the Code
Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.
Should Immunotherapy Change the Practice for Esophageal and Gastric Cancer in the Near Future?
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.
Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.
Highlights of the Metastatic Breast Cancer Session
Antiangiogenic and Targeted Therapies With or Without Anti-PD1/Anti-PD-L1
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study).